LUNG Pulmonx

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at .

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit .

Contact

Brian Johnston

Gilmartin Group



EN
22/08/2024

Underlying

LUNGPulmonx

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pulmonx

 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Reports Second Quarter 2025 Financial Results

Pulmonx Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15% increase over the same period last year and an increase of 13% on a constant currency basisDelivered $9.1 million in international revenue in the second quart...

July 30, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Confere...

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at . About Pulmonx CorporationPulmonx...

July 29, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 20...

Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025 REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “...

July 16, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare ...

Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at . About Pulmonx Corporation ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Present at the Bank of America Securities 2025 Health Care ...

Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at . About Pulmonx CorporationPulmonx Corpora...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch